Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Partnerships Target Protein Enhancement

by Michael McCoy
May 25, 2009 | A version of this story appeared in Volume 87, Issue 21

Two pairs of companies have signed deals around technology that improves the availability and longevity of pharmaceutical proteins in the body. Fresenius Kabi and Bayer Schering Pharma have signed a research, development, and licensing agreement that gives Bayer access to Fresenius' HESylation technology, in which drugs are modified with hydroxyethyl starch. Meanwhile, Novozymes and Human Genome Sciences have revised an agreement over Novozymes' Albufuse, a technology for fusing protein drugs with albumin. Novozymes says the revision gives it the "necessary platform" to commercially exploit the process.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.